Christopher Lieu, MD

For patients, clinical trials often give them access to treatments and/or procedures that they otherwise would not have access to.

Christopher Lieu, MD

Meet the Experts

We are proud to work with some of the most world-renowned researchers in the colorectal cancer field through our Medical-Scientific Advisory Committee. These experts provide us knowledge and insight into the “latest and greatest” research currently being conducted around the world.

Knowing that research is key to knocking colon cancer out of the top three cancer killers, we are committed to supporting researchers who are leaders in the field, working in some of the most prestigious institutions in the country.


John Marshall, MD is a global leader in the research and development of drugs for colon cancer and other GI cancers. He is the principal investigator of over 150 clinical trials, at the local as well as national levels. Dr. Marshall is the clinical director of oncology for Georgetown University Hospital, associate director for clinical care of the Lombardi Comprehensive Cancer Center, and chief of the Division of Hematology-Oncology. In 2009, Dr. Marshall became the founding director of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer. Combining expertise in molecular medicine, translational research, and a patient-centered philosophy, the Ruesch Center is dedicated to realizing the dream of individualized curative therapies through research, care and advocacy. Dr. Marshall’s own research focuses on the development of a novel vaccine for the treatment of advanced colon cancer. For over a decade, he has directed Lombardi’s Developmental Therapeutics Program while also maintaining his regular clinical practice. Seeing about 60 patients each week, Dr. Marshall specializes in cancers of the GI tract at all stages of the disease.


Edward Chu, MD is involved in basic, clinical, and translational cancer research. His basic research interests have focused on characterization of the molecular mechanisms underlying the development of cellular drug resistance, especially as it relates to the fluoropyrimidine class of anticancer agents. His research group was the first to identify translational autoregulation as a novel regulatory mechanism in eukaryotes for controlling the expression of the folate-dependent enzymes, thymidylate synthase and dihydrofolate reductase. His clinical translational research efforts have focused on identifying novel drugs and treatment strategies for colorectal cancer and other GI cancers and in developing early-phase I/II clinical trials. He has a strong interest in integrating Chinese herbal medicine with standard cancer chemotherapy with the goal of enhancing clinical activity and reducing the toxicity associated with chemotherapy.


Dr. Anthony F. Shields, MD, PhD has been dedicated to clinical research and the care of patients with colorectal, pancreatic and other gastrointestinal cancers. His experiences in research and the clinic make him painfully aware of the need to develop new approaches in understanding and overcoming resistance to treatment for patients with GI cancer. At Karmanos Cancer Institute and Wayne University School of Medicine he leads clinical research efforts through his roles as the Associate Center Director for Clinical Sciences, Program Leader in Molecular Imaging and Diagnostics and Professor of Oncology and Medicine. In the clinic, his work concentrates on the treatment of patients with gastrointestinal (GI) cancer and he continues to develop and lead new clinical trials for GI tumors. His laboratory research focuses on the development and testing of tracers for use with positron emission tomography (PET) for the assessment of a variety of tumors (e.g. brain, lung, breast, and prostate cancers) and their response to treatment. Dr. Shields led the development of FLT {3′-deoxy-3′-fluorothymidine}; a promising tracer for tumor proliferation, which has received an IND from the FDA and is being tested in centers worldwide.


Dr. Christopher Lieu, MD is a member of the Developmental Therapeutics (Phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Program.   These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors.  Dr. Lieu is interested in resistance mechanisms to targeted therapy in GI cancers, and he was awarded the Conquer Cancer Foundation Career Development Award and an NIH K23 grant to study targeted therapies in colorectal cancer.  Dr. Lieu is also investigating novel therapeutic strategies to treat more effectively or prevent colorectal cancer in young adults.


Dr. Marios Giannakis, MD, PhD is a medical oncologist and clinical investigator at the Dana-Farber Gastrointestinal Cancer Center. He also conducts research at Dana-Farber and the Broad Institute of MIT and Harvard to understand the molecular mechanisms of colorectal cancer formation and develop novel targeted and immune-based treatments for gastrointestinal cancers. Dr. Giannakis was the 2014 Blue Hope Research Award recipient.


Dr. Tatiana Larman, MD (2nd from left) is currently a pathology resident at Johns Hopkins and Dr. Sarah Stringfield (3rd from left) is an Associate Physician in the University of California- San Diego’s Surgery Department. Drs. Larman and Stringfield were the 2016 recipients of the Never Too Young Coalition/AACR Research Award, which was made possible by the Colon Cancer Alliance and Michael’s Mission.